Peptides News and Research

RSS

Identification of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding

Researchers discovered compounds able to inhibit SARS-CoV-2 macrodomain 1 and adenosine diphosphate-ribose binding via high throughput screening.

7 Mar 2022

Researchers design a peptide hydrogel for cell spheroids production

This study is led by Prof. Zhimou Yang and Prof. Quan Chen (College of Life Sciences in Nankai University), and Prof. Jianfeng Liu (Institute of Radiation Medicine, Chinese Academy of Medical Sciences). Prof. Zhimou Yang, who is working in the research field of peptide self-assembly biomaterials for more than 15 years, designed the peptide hydrogel for cell spheroids production.

4 Mar 2022

Novel approach to generate reliable breast tumor models may pave way for better immunotherapies

The discrepancy between preclinical advances in breast cancer immunotherapy and poor patient outcomes is rooted in the limitations of current breast cancer models. These models often fail to mimic complex interactions between cancer cells and key immune cells present in the tumor microenvironment.

3 Mar 2022

Assessing the potential of IFNa subtypes in suppressing SARS-CoV-2

A recent study analyzes IFNa subtypes for their therapeutic potential against SARS-CoV-2 and identified the underlying immune signatures and mechanisms.

3 Mar 2022

Scientists discover an innate form of immunological memory in the intestine

The innate immune system plays a crucial role in regulating host-microbe interactions, and especially in providing protection against pathogens that invade the mucosa.

28 Feb 2022

Peptide-based vaccine fails to protect mice against SARS-CoV-2 despite T cell response

A recent study observed that peptide-based vaccination against SARS-CoV-2 failed to protect mice against COVID-19, albeit eliciting T cell responses.

28 Feb 2022

Immune responses in patients with varying degrees of SARS-CoV-2 infection

In a recent research article published in the journal PLoS ONE, researchers looked at immunological responses in relation to established risk factors for serious illness. This prospective cohort study reports on long-lasting SARS-CoV-2 specific antibody and T-cellular immune responses six months after infection in rt-PCR confirmed cases of different illness severity (community and hospitalized patients).

24 Feb 2022

Study proposes SARS-CoV-2-encoded peptide presented by HLA-E may suppress inhibition of natural killer cells

A recent study reported the abrogation of inhibition of the NK cells by a SARS-CoV-2-encoded protein presented by HLA-E.

23 Feb 2022

TTUHSC expert wins NIH renewal grant to continue research on neurological disorders

According to the Global Burden of Disease study, neurological disorders are the leading cause of disability and the second leading cause of death after heart disease.

21 Feb 2022

Gradual decline in pathogenicity and enhanced cytokine induction in SARS-CoV-2 variants

A new study focuses on understanding the factors associated with the ability of the Omicron variant to infect a wide range of age groups.

20 Feb 2022

N-glycosylation blockers reduce SARS-CoV-2 infection

A new Virology study shows that the N-glycosylation pattern of SARS-CoV-2 is crucial to normal spike activity.

20 Feb 2022

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science's journal, Science Advances.

18 Feb 2022

New finding may aid in development of vaccines against future animal-to-human viral diseases

A future vaccine providing protection against a wide range of coronaviruses that jump from their original animal hosts to humans - including SARS-CoV-2, the cause of COVID-19 - may be possible, say Johns Hopkins Medicine researchers, based on findings from their recent study.

17 Feb 2022

Study explores differential immune responses against SARS-CoV-2 in adults and children

A new study revealed that the immune responses against SARS-CoV-2 and the clinical course of COVID-19 differs between children and adults.

17 Feb 2022

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

A new study discusses the state of current knowledge about the potential use of tea polyphenols in the prevention and treatment of COVID-19.

16 Feb 2022

Prediction of SARS-CoV-2 epitope candidates for future vaccines

Researchers identify and investigate the presence and evolution of the SARS-CoV-2 N and S glycoprotein proteins.

15 Feb 2022

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

In a new study, researchers investigated whether neutralizing antibodies against the SARS-CoV-2 spike protein offered adequate immunity against breakthrough infections among vaccinated individuals.

15 Feb 2022

Testes found to be a viral reservoir for SARS-CoV-2 replication

In a recent study posted to the medRxiv* pre-print server, researchers used a suite of methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the testis of patients who died from coronavirus disease 2019 (COVID-19) to gain insights into SARS-CoV-2 tropism inside testis and its impact on male fertility.

13 Feb 2022

New COVID-19 test can determine if individuals have been vaccinated, infected, both, or neither

Researchers have created a new T cell assay that allows discrimination of COVID-19 infection and vaccination, as well as the order in which these occurred.

11 Feb 2022

Impact of genetic changes in Omicron variant on an immunodominant T-cell epitope

Researchers describe the impact of changes in the Omicron variant on a uniquely immunodominant spike-encoded CD8+ T-cell epitope.

9 Feb 2022